A detailed history of Voya Investment Management LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 16,855 shares of ALDX stock, worth $80,735. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,855
Previous 17,664 4.58%
Holding current value
$80,735
Previous $58,000 55.17%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.19 - $6.32 $2,580 - $5,112
-809 Reduced 4.58%
16,855 $90,000
Q2 2024

Dec 03, 2024

BUY
$3.25 - $4.72 $2,629 - $3,818
809 Added 4.8%
17,664 $58,000
Q2 2024

Aug 14, 2024

BUY
$3.25 - $4.72 $5,128 - $7,448
1,578 Added 9.81%
17,664 $58,000
Q1 2024

Dec 06, 2024

SELL
$2.77 - $4.22 $2,130 - $3,245
-769 Reduced 4.56%
16,086 $52,000
Q1 2024

May 15, 2024

SELL
$2.77 - $4.22 $8,996 - $13,706
-3,248 Reduced 16.8%
16,086 $52,000
Q3 2023

Nov 14, 2023

BUY
$6.11 - $8.16 $4,417 - $5,899
723 Added 3.88%
19,334 $129,000
Q2 2023

Aug 14, 2023

BUY
$7.11 - $11.89 $132,324 - $221,284
18,611 New
18,611 $156,000
Q2 2022

Aug 15, 2022

SELL
$2.43 - $4.85 $45,324 - $90,462
-18,652 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$3.5 - $9.63 $1,557 - $4,285
-445 Reduced 2.33%
18,652 $75,000
Q2 2021

Aug 16, 2021

BUY
$10.44 - $14.85 $199,372 - $283,590
19,097 New
19,097 $216,000
Q2 2020

Aug 14, 2020

SELL
$1.97 - $5.05 $28,348 - $72,669
-14,390 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$4.73 - $7.98 $16,696 - $28,169
3,530 Added 32.5%
14,390 $84,000
Q2 2019

Aug 14, 2019

BUY
$6.0 - $9.0 $65,160 - $97,740
10,860 New
10,860 $65,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $279M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.